Every Form 4 that OptimizeRx Corporation (OPRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OPRX filings page.
OptimizeRx Corp (OPRX) Chief Business Officer Andrew J. D'Silva had 414 shares withheld by the issuer on October 1, 2026, upon vesting of restricted stock units to satisfy tax withholding obligations. The reported price was $8.39 per share; his resulting direct holdings were 99,246 shares.
OptimizeRx Corp (OPRX) reported that Chief Business Officer Andrew J. D'Silva had 1,432 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units, treated as a disposition under Section 16, at a value of $7.86 per share. After this withholding, he directly holds 99,660 shares of OptimizeRx common stock, and no Rule 10b5-1 trading plan is reported.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (OPRX) reported an insider transaction by Chief Operating Officer Brendan W. Merrell. On 2026-08-21, 1,020 shares of common stock were withheld at $7.71 per share to satisfy tax withholding obligations upon the vesting of restricted stock units. This withholding is treated as a disposition under Section 16, and Merrell now holds 25,187 shares of common stock directly.
OptimizeRx Corp (OPRX) reported that Chief Executive Officer Stephen L. Silvestro had 1,737 shares of Common Stock withheld on 2026-08-21 to satisfy his tax withholding obligations upon the vesting of restricted stock units. This Code F transaction is treated as a disposition under Section 16, and Silvestro now holds 183,551 shares of OptimizeRx common stock directly.
OptimizeRx Corp (OPRX) reported that Chief Legal & Admin Officer Marion Odence-Ford had 1,529 shares of common stock withheld on 2026-08-21 to satisfy tax withholding obligations upon vesting of restricted stock units. This withholding is treated as a disposition under Section 16. After this transaction, Odence-Ford directly held 90,407 shares of OptimizeRx common stock.
OptimizeRx Corp (OPRX) reported that Chief Business Officer Andrew J. D'Silva had 1,243 shares of common stock withheld on August 21, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units. The withholding, treated as a disposition under Section 16, left him with 43,492 directly held shares.
OptimizeRx Corp (OPRX) reported an insider Form 4 for Edward Stelmakh, Chief Finance & Strat Officer. On 2026-08-21, 1,381 shares of common stock were disposed of under code F at $7.71 per share, representing shares delivered or withheld for payment of exercise price or tax liability. Following this transaction, Stelmakh’s reported direct holdings total 121,791 shares of OptimizeRx common stock. A footnote states that the filing should not be construed as an admission of beneficial ownership or that the filing is legally required.
KLEMA CATHY reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director Cathy Klema reported an equity grant of 34,517 restricted stock units (RSUs) tied to the company’s common stock. The RSUs were awarded on June 9, 2026 at no cash purchase price and represent a contingent right to receive shares.
The RSUs will vest in full on the earlier of the first anniversary of the grant date or the date of OptimizeRx’s next annual meeting of shareholders. Following this grant, Klema’s direct holdings reported in the filing total 56,137 shares of common stock. The transaction is characterized as a grant or award rather than an open-market buy or sell.
Lang James Paul reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director James Paul Lang reported an equity award of 34,517 shares of common stock. The filing describes this as a grant of restricted stock units, representing a contingent right to receive shares of OptimizeRx common stock at no purchase price.
The restricted stock units will vest in full on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of shareholders. Following this award, Lang is reported as directly owning 433,837 shares of OptimizeRx common stock.
Presti Mariyamma Varghese reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director Presti Mariyamma Varghese received a grant of 17,258 restricted stock units (RSUs) of common stock. The award was made at no cash cost per unit and increases her direct holdings to 30,318 shares after the transaction. The RSUs represent a contingent right to receive shares that will vest in full on the earlier of the first anniversary of the grant date or the date of OptimizeRx’s next annual meeting of shareholders.
Spangler Patrick D reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director Patrick D. Spangler received an equity award of 34,517 shares of common stock in the form of restricted stock units. The units carry a contingent right to receive OptimizeRx common stock and will vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the company’s next annual meeting of shareholders. Following this grant, he directly owns 78,732 shares of common stock.
Vos Ellen O'Connor reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director Ellen O'Connor Vos received an equity grant of 34,517 shares of common stock in the form of restricted stock units. The award was granted for no cash consideration as compensation and increases her direct holdings to 107,159 common shares.
The restricted stock units will vest in full on the earlier of the first anniversary of the grant date or the date of OptimizeRx's next annual meeting of shareholders, aligning her compensation with future company performance and shareholder timelines.
WASSON GREGORY D reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director Gregory D. Wasson received an equity award of 34,517 restricted stock units (RSUs). These RSUs represent a contingent right to receive shares of OptimizeRx common stock as part of his director compensation, at no cash purchase price.
The RSUs will vest in full on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of shareholders. After this grant, Wasson directly holds 91,700 shares of OptimizeRx common stock, reflecting his ongoing equity stake in the company.
Presti Mariyamma Varghese reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director Mariyamma Varghese Presti reported an award of equity-based compensation. She received 13,060 restricted stock units representing a contingent right to receive shares of OptimizeRx common stock, granted at no cash cost on May 1, 2026.
The restricted stock units will vest in full on the first anniversary of the grant date. Following this grant, the filing shows direct ownership of 13,060 shares or share equivalents tied to this award.
OptimizeRx Corp Chief Commercial Officer Theresa Greco reported routine tax-related share dispositions. On May 15, 2026, the company withheld 879 and 914 shares of Common Stock at $5.21 per share to cover her tax obligations upon vesting of restricted stock units. The footnote explains these withholdings are treated as dispositions under Section 16 rules, but they were not open-market sales and reflect standard equity-compensation tax treatment.
OptimizeRx Corp Chief Executive Officer Stephen L. Silvestro reported a tax-related share disposition tied to vesting equity awards. On this Form 4, 5,219 shares of common stock were withheld by the company on May 15, 2026 at a value of $5.21 per share to cover his tax withholding obligations upon vesting of restricted stock units. The filing notes this withholding is treated as a disposition under Section 16 rules, but it is not an open-market sale. After the transaction, Silvestro directly owned 185,288 shares of OptimizeRx common stock, so the withheld amount represents a small portion of his overall reported holdings.
OptimizeRx Corp’s Chief Legal & Admin Officer, Marion Odence-Ford, reported routine equity compensation activity. On February 11, 2026, 4,000 restricted stock units converted into 4,000 shares of common stock on a one-for-one basis.
To cover tax withholding obligations, 1,386 common shares were withheld by the company at $9.23 per share and treated as a disposition for reporting purposes. After these transactions, Odence-Ford directly beneficially owned 91,936 shares of OptimizeRx common stock.
OptimizeRx Corp's chief operating officer reported an insider stock transaction involving company common shares. On December 11, 2025, 712 shares of common stock were withheld by the company upon the vesting of restricted stock units to satisfy the officer's tax withholding obligations, at a price of $14.03 per share. This is treated under securities rules as a disposition even though it reflects tax withholding rather than an open-market sale.
After this transaction, the officer beneficially owned 26,496 shares of OptimizeRx common stock in direct form. The statement also notes that it should not be construed as an admission of beneficial ownership or that the filing was legally required.
OptimizeRx Corp's chief business officer reported a tax-related disposition of 868 shares of common stock, tied to the vesting of restricted stock units on 12/11/2025.
The issuer withheld these shares at a price of $14.03 per share to satisfy the officer's tax withholding obligations, which is treated as a disposition under Section 16 rules. After this transaction, the officer directly owns 45,438 shares of OptimizeRx common stock.
OptimizeRx (OPRX) reported insider equity awards for its Chief Operating Officer. On August 21, 2025, the officer received 10,417 restricted stock units at $0 and a stock option for 23,437 shares at an exercise price of $16.14. Both awards vest in three equal annual installments beginning August 21, 2026.
On October 3, 2025, 483 shares were withheld at $18.75 to satisfy tax obligations. Following the reported transactions, directly held common stock was 27,691 after the grant and 27,208 after the withholding.
OptimizeRx Corp (OPRX) reported insider activity on Form 4 for its Chief Business Officer. The filing shows issuer tax withholdings (Transaction Code F) related to equity compensation. On 10/01/2025, 414 shares of common stock were withheld at $18.98. On 10/03/2025, 794 shares were withheld at $18.75. Following these transactions, the reporting person held 46,306 shares directly. The explanation states the shares were withheld by the issuer to satisfy tax obligations and are treated as dispositions under Section 16.
OptimizeRx Corp (OPRX) reported an insider transaction on a Form 4 by its Chief Commercial Officer. On 11/01/2025, 1,693 shares of common stock were withheld by the company to cover taxes due upon the vesting of restricted stock units, a transaction reported with code F at a price of $20.49.
Following this tax withholding event, the reporting person beneficially owns 74,288 shares, held directly. The filing notes that such tax withholding is treated as a disposition under Section 16.